Author: "Judd, Ali" / Topic: immunology - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Judd, Ali"' showing total 19 results

Start Over Author "Judd, Ali" Topic immunology

19 results on '"Judd, Ali"'

1. Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation

Author: European Infant Collaboration Group, Goetghebuer, Tessa, Le Chenadec, Jerome, Haelterman, Edwige, Galli, Luisa, Dollfus, Catherine, Thorne, Claire, Judd, Ali, Keiser, Olivia, Ramos, Jose Tomas, Levy, Jack, and Warszawski, Josiane
Published: 2012
Full Text: View/download PDF

2. Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand

Author: Crichton, Siobhan, Belfrage, Eric, Collins, Intira Jeanne, Doerholt, Katja, Judd, Ali, Le Coeur, Sophie, Spoulou, Vana, Goodall, Ruth, Scherpbier, Henriette, Smit, Colette, Goetghebuer, Tessa, Gibb, Diana M., Noguera, Antoni, Luisa Navarro, Maria, Tomas Ramos, Jose, Galli, Luisa, Giaquinto, Carlo, Thorne, Claire, Santa Ansone, Marczynska, Magdalena, Okhonskaia, Liubov, de Tejada, Begona Martinez, Jourdain, Gonzague, Decker, Luc, Ene, Luminita, Hainaut, Marc, Van der Kelen, Evelyne, Delforge, Marc, de Martino, Maurizio, Tovo, Pier Angelo, Patrizia, Osimani, Larovere, Domenico, Ruggeri, Maurizio, Faldella, Giacomo, Baldi, Francesco, Badolato, Raffaele, Montagnani, Carlotta, Venturini, Elisabetta, Lisi, Catiuscia, Di Biagio, Antonio, Taramasso, Lucia, Giacomet, Vania, Erba, Paola, Esposito, Susanna, Lipreri, Rita, Salvini, Filippo, Tagliabue, Claudia, Cellini, Monica, Bruzzese, Eugenia, Lo Vecchio, Andrea, Rampon, Osvalda, Dona, Daniele, Romano, Amelia, Dodi, Icilio, Maccabruni, Anna, Consolini, Rita, Bernardi, Stefania, Kuekou, Hyppolite Tchidjou, Genovese, Orazio, Olmeo, Paolina, Cristiano, Letizia, Mazza, Antonio, Gabiano, Clara, Garazzino, Silvia, Pellegatta, Antonio, Pajkrt, D., Scherpbier, H. J., Weijsenfeld, A. M., de Boer, C. G., Jurriaans, S., Back, N. K. T., Zaaijer, H. L., Berkhout, B., Cornelissen, M. T. E., Schinkel, C. J., Wolthers, K. C., Fraaij, P. L. A., van Rossum, A. M. C., Vermont, C. L., van der Knaap, L. C., Visser, E. G., Boucher, C. A. B., Koopmans, M. P. G., van Kampen, J. J. A., Pas, S. D., Henriet, S. S., V, van de Flier, M., van Aerde, K., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, F. F., Scholvinck, E. H., de Groot-de Jonge, H., Niesters, H. G. M., van Leer-Buter, C. C., Knoester, M., Bont, L. J., Geelen, S. P. M., Wolfs, T. F. W., Nauta, N., Schuurman, R., Verduyn-Lunel, F., Wensing, A. M. J., Reiss, P., Zaheri, S., Bezemer, D. O., van Sighem, A., I, Smit, C., Wit, F. W. M. N., Hillebregt, M., de Jong, A., Woudstra, T., Bergsma, D., Grivell, S., Meijering, R., Raethke, M., Rutkens, T., de Groot, L., van den Akker, M., Bakker, Y., Bezemer, M., El Berkaoui, A., Geerlinks, J., Koops, J., Kruijne, E., Lodewijk, C., Lucas, E., van der Meer, R., Munjishvili, L., Paling, E., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., van de Sande, L., Schoorl, M., Schnorr, P., Tuijn, E., Veenenberg, L., van der Vliet, S., Wisse, A., Witte, E. C., Tuk, B., Popielska, Jolanta, Pokorska-Spiewak, Maria, Oldakowska, Agnieszka, Zawadka, Konrad, Coupland, Urszula, Doroba, Malgorzata, Voronin, Evgeny, Miloenko, Milana, Labutina, Svetlana, Soler-Palacin, Pere, Antoinette Frick, Maria, Perez-Hoyos, Santiago, Mur, Antonio, Lopez, Nuria, Mendez, Maria, Mayol, Lluis, Vallmanya, Teresa, Calavia, Olga, Garcia, Lourdes, Coll, Maite, Pineda, Valenti, Rius, Neus, Rovira, Nuria, Duenas, Joaquin, Gamell, Anna, Fortuny, Claudia, Noguera-Julian, Antoni, Jose Mellado, Maria, Escosa, Luis, Garcia Hortelano, Milagros, Sainz, Talia, Isabel Gonzalez-Tome, Maria, Rojo, Pablo, Blazquez, Daniel, Prieto, Luis, Guillen, Sara, Saavedra, Jesus, Santos, Mar, Angeles Munoz, Ma, Ruiz, Beatriz, Fernandez Mc Phee, Carolina, Jimenez de Ory, Santiago, Alvarez, Susana, Angel Roa, Miguel, Beceiro, Jose, Martinez, Jorge, Badillo, Katie, Apilanez, Miren, Pocheville, Itziar, Garrote, Elisa, Colino, Elena, Gomez Sirvent, Jorge, Garzon, Monica, Roman, Vicente, Montesdeoca, Abian, Mateo, Mercedes, Jose Munoz, Maria, Angulo, Raquel, Neth, Olaf, Falcon, Lola, Terol, Pedro, Luis Santos, Juan, Moreno, David, Lendinez, Francisco, Grande, Ana, Jose Romero, Francisco, Perez, Carlos, Lillo, Miguel, Losada, Begona, Herranz, Mercedes, Bustillo, Matilde, Guerrero, Carmelo, Collado, Pilar, Antonio Couceiro, Jose, Perez, Amparo, Isabel Piqueras, Ana, Breton, Rafael, Segarra, Inmaculada, Gavilan, Cesar, Jareno, Enrique, Montesinos, Elena, Dapena, Marta, Alvarez, Cristina, Gloria Andres, Ana, Marugan, Victor, Ochoa, Carlos, Alfayate, Santiago, Isabel Menasalvas, Ana, de Miguel, Elisa, Naver, Lars, Soeria-Atmadja, Sandra, Hagas, Vendela, Aebi-Popp, K., Anagnostopoulos, A., Asner, S., Battegay, M., Baumann, M., Bernasconi, E., Boni, J., Braun, D. L., Bucher, H. C., Calmy, A., Cavassini, M., Ciuffi, A., Duppenthaler, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Francini, K., Furrer, H., Fux, C. A., Grawe, C., Gunthard, H. F., Haerry, D., Hasse, B., Hirsch, H. H., Hoffmann, M., Hosli, I, Huber, M., Kahlert, C. R., Kaiser, L., Keiser, O., Klimkait, T., Kottanattu, L., Kouyos, R. D., Kovari, H., Ledergerber, B., Martinetti, G., de Tejada, Martinez B., Marzolini, C., Metzner, K. J., Mueller, N., Nicca, D., Paioni, P., Pantaleo, G., Perreau, M., Polli, Ch, Rauch, A., Rudin, C., Scherrer, A. U., Schmid, P., Speck, R., Stockle, M., Tarr, P., Lecompte, Thanh M., Trkola, A., Vernazza, P., Wagner, N., Wandeler, G., Weber, R., Wyler, C. A., Yerly, S., Wannarit, Pornpun, Techakunakorn, Pornchai, Hansudewechakul, Rawiwan, Wanchaitanawong, Vanichaya, Theansavettrakul, Sookchai, Nanta, Sirisak, Ngampiyaskul, Chaiwat, Phanomcheong, Siriluk, Hongsiriwon, Suchat, Karnchanamayul, Warit, Kwanchaipanich, Ratchanee, Kanjanavanit, Suparat, Kamonpakorn, Nareerat, Nantarukchaikul, Maneeratn, Layangool, Prapaisri, Mekmullica, Jutarat, Lucksanapisitkul, Paiboon, Watanayothin, Sudarat, Lertpienthum, Narong, Warachit, Boonyarat, Hanpinitsak, Sansanee, Potchalongsin, Sathit, Thanasiri, Pimpraphai, Krikajornkitti, Sawitree, Attavinijtrakarn, Pornsawan, Srirojana, Sakulrat, Bunjongpak, Suthunya, Puangsombat, Achara, Na-Rajsima, Sathaporn, Ananpatharachai, Pornchai, Akarathum, Noppadon, Lawtongkum, Weerasak, An, Prapawan Kheunj, Suriyaboon, Thitiporn, Saipanya, Airada, Than-in-at, Kanchana, Jaisieng, Nirattiya, Suaysod, Rapeepan, Chailoet, Sanuphong, Naratee, Naritsara, Kawilapat, Suttipong, Lyall, Hermione, Bamford, Alasdair, Butler, Karim, Doherty, Conor, Foster, Caroline, Francis, Kate, Harrison, Ian, Kenny, Julia, Klein, Nigel, Letting, Gillian, McMaster, Paddy, Murau, Fungai, Nsangi, Edith, Peters, Helen, Prime, Katia, Riordan, Andrew, Shackley, Fiona, Shingadia, Delane, Storey, Sharon, Tudor-Williams, Gareth, Turkova, Anna, Welch, Steve, Collins, Intira Jeannie, Cook, Claire, Dobson, Donna, Fairbrother, Keith, Harper, Lynda, Le Prevost, Marthe, Van Looy, Nadine, Butler, K., Walsh, A., Thrasyvoulou, L., Welch, S., Bernatoniene, J., Manyika, F., Sharpe, G., Subramaniam, B., Sloper, K., Fidler, K., Hague, R., Price, V, Clapson, M., Flynn, J., Abou-Rayyah, A. Cardoso M., Klein, N., Shingadia, D., Gurtin, D., Yeadon, S., Segal, S., Ball, C., Hawkins, S., Dowie, M., Bandi, S., Percival, E., Eisenhut, M., Duncan, K., Clough, S., Anguvaa, L., Conway, S., Flood, T., Pickering, A., Murphy, P. McMaster C., Daniels, J., Lees, Y., Thompson, F., Williams, B., Pope, S., Cliffe, L., Smyth, A., Southall, S., Freeman, A., Freeman, H., Christie, S., Gordon, A., Clarke, D. Rogahn L., Jones, L., Offerman, B., Greenberg, M., Benson, C., Riordan, A., Ibberson, L., Shackley, F., Faust, S. N., Hancock, J., Doerholt, K., Prime, K., Sharland, M., Storey, S., Lyall, H., Monrose, C., Seery, P., Tudor-Williams, G., Menson, E., Callaghan, A., Bridgwood, A., McMaster, P., Evans, J., Blake, E., Yannoulias, A., European Pregnancy Paediat HIV Coh, Microbes in Health and Disease (MHD), Fundación Investigación y Educación en Sida, Instituto de Salud Carlos III, European Commission, Fundación Mutua Madrileña, Épidémiologie clinique, santé mère-enfant et VIH en Asie du Sud-Est (IRD_PHPT), Harvard University [Cambridge]-Chiang Mai University (CMU), Pediatrics, and Virology
Subjects: 0301 basic medicine, Male, Pediatrics, puberty, [SDV]Life Sciences [q-bio], humanos, Human immunodeficiency virus (HIV), adolescente, LETTONIE, CHILDREN, HIV Infections, medicine.disease_cause, GRECE, desarrollo del niño, Cohort Studies, 0302 clinical medicine, Child Development, CHILD_DEVELOPMENT, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, ADOLESCENTS, Immunology and Allergy, Pooled data, 030212 general & internal medicine, SUEDE, Child, estudios de cohortes, ESPAGNE, 11 Medical and Health Sciences, Anthropometry, THAILANDE, Europe, growth, height, HIV, perinatal, Thailand, Adolescent, Anti-Retroviral Agents, Child, Preschool, Female, Humans, Infant, Puberty, virus diseases, Growth spurt, PAYS BAS, 3. Good health, 17 Psychology and Cognitive Sciences, AIDS, antirretrovirales, Infectious Diseases, POLOGNE, BELGIQUE, Life Sciences & Biomedicine, medicine.medical_specialty, Pediatric hiv, Epidemiology and Social, ROYAUME UNI, Immunology, MASS, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Virology, medicine, pubertad, Preschool, lactante, ROUMANIE, Science & Technology, business.industry, 06 Biological Sciences, VELOCITY, SUISSE, Regimen, 030104 developmental biology, VIRAL LOAD, antropometría, infecciones por VIH, BODY_HEIGHT, business, IRLANDE, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group., [Objective]: The aim of this study was to describe growth during puberty in young people with vertically acquired HIV. [Design]: Pooled data from 12 paediatric HIV cohorts in Europe and Thailand. [Methods]: One thousand and ninety-four children initiating a nonnucleoside reverse transcriptase inhibitor or boosted protease inhibitor based regimen aged 1–10 years were included. Super Imposition by Translation And Rotation (SITAR) models described growth from age 8 years using three parameters (average height, timing and shape of the growth spurt), dependent on age and height-for-age z-score (HAZ) (WHO references) at antiretroviral therapy (ART) initiation. Multivariate regression explored characteristics associated with these three parameters. [Results]: At ART initiation, median age and HAZ was 6.4 [interquartile range (IQR): 2.8, 9.0] years and −1.2 (IQR: −2.3 to −0.2), respectively. Median follow-up was 9.1 (IQR: 6.9, 11.4) years. In girls, older age and lower HAZ at ART initiation were independently associated with a growth spurt which occurred 0.41 (95% confidence interval 0.20–0.62) years later in children starting ART age 6 to 10 years compared with 1 to 2 years and 1.50 (1.21–1.78) years later in those starting with HAZ less than −3 compared with HAZ at least −1. Later growth spurts in girls resulted in continued height growth into later adolescence. In boys starting ART with HAZ less than −1, growth spurts were later in children starting ART in the oldest age group, but for HAZ at least −1, there was no association with age. Girls and boys who initiated ART with HAZ at least −1 maintained a similar height to the WHO reference mean. [Conclusion]: Stunting at ART initiation was associated with later growth spurts in girls. Children with HAZ at least −1 at ART initiation grew in height at the level expected in HIV negative children of a comparable age., This work has been partially funded by the Fundación para la Investigación y Prevención de SIDA en España (FIPSE) (FIPSE 3608229/09, FIPSE 240800/09, FIPSE 361910/10), Red Temática de Investigación en SIDA (RED RIS) supported by Instituto de Salud Carlos III (ISCIII) (RD12/0017/0035 and RD12/0017/0037), project as part of the Plan R+D+I and cofinanced by ISCIII- Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (FEDER),Mutua Madrileña 2012/0077, Gilead Fellowship 2013/0071, FIS PI15/00694,CoRISpe (RED RIS RD06/0006/0035 y RD06/0006/0021).
Published: 2019
Full Text: View/download PDF

3. Predictors of faster virological suppression in early treated infants with perinatal HIV from Europe and Thailand

Author: Chan, Man K., Goodall, Ruth, Judd, Ali, Klein, Nigel, Chiappini, Elena, Klimkait, Thomas, Ngo-Giang-Huong, Nicole, Palma, Paolo, Rossi, Paolo, Thorne, Claire, Turkova, Anna, Zangari, Paola, Fraaij, Pieter L., Pajkrt, Dasja, Marques, Laura, Collins, Intira J., Gibb, Diana M., Gonzalez-Tome, Maria I., Navarro, Maria L., Ramos, Jose T., Noguera-Julian, Antoni, Warszawski, Josiane, Königs, Christoph, Spoulou, Vana, Prata, Filipa, Goetghebuer, Tessa, Galli, Luisa, Naver, Lars, Giaquinto, Carlo, Marczynska, Magdalena, Okhonskaia, Liubov, Malyuta, Ruslan, Volokha, Alla, Ene, Luminita, Rojo, Pablo, and Babiker, Abdel G. A.
Subjects: Male, 0301 basic medicine, Pediatrics, Sustained Virologic Response, Sida en l'embaràs, HIV Infections, Cohort Studies, 0302 clinical medicine, immune system diseases, Interquartile range, Antiretroviral Therapy, Highly Active, Immunology and Allergy, 030212 general & internal medicine, infants, Hazard ratio, Age Factors, virus diseases, Viral Load, Clinical Science, Thailand, 3. Good health, Europe, Infectious Diseases, Cohort, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Disease Progression, Reverse Transcriptase Inhibitors, Female, Viral load, virological suppression, Cohort study, Cart, medicine.medical_specialty, Immunology, Drug Administration Schedule, 03 medical and health sciences, mental disorders, medicine, VIH (Virus), Humans, early combination antiretroviral therapy, Pregnancy, Proportional hazards model, business.industry, HIV (Viruses), Infant, Newborn, Infant, HIV Protease Inhibitors, medicine.disease, CD4 Lymphocyte Count, AIDS (Disease) in pregnancy, predictors, 030104 developmental biology, nervous system, Drug withdrawal symptoms, Multivariate Analysis, Síndrome d'abstinència, business, perinatal HIV
Abstract: Supplemental Digital Content is available in the text, Objective: To identify predictors of faster time to virological suppression among infants starting combination antiretroviral therapy (cART) early in infancy. Design: Cohort study of infants from Europe and Thailand included in studies participating in the European Pregnancy and Paediatric HIV Cohort Collaboration. Methods: Infants with perinatal HIV starting cART aged less than 6 months with at least 1 viral load measurement within 15 months of cART initiation were included. Multivariable interval-censored flexible parametric proportional hazards models were used to assess predictors of faster virological suppression, with timing of suppression assumed to lie in the interval between last viral load at least 400 and first viral load less than 400 copies/ml. Results: Of 420 infants, 59% were female and 56% from Central/Western Europe, 26% United Kingdom/Ireland, 15% Eastern Europe and 3% Thailand; 46 and 54% started a boosted protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based regimen, respectively. At cART initiation, the median age, CD4+% and viral load were 2.9 [interquartile range (IQR): 1.4–4.1] months, 34 (IQR: 24–45)% and 5.5 (IQR: 4.5–6.0) log10 copies/ml, respectively. Overall, an estimated 89% (95% confidence interval: 86–92%) achieved virological suppression within 12 months of cART start. In multivariable analysis, younger age [adjusted hazard ratio (aHR): 0.84 per month older; P
Published: 2019

4. Sexual health of young people with perinatal HIV and HIV negative young people in England

Author: Judd, Ali, Foster, Caroline, Thompson, Lindsay C., Sturgeon, Kate, Le Prevost, Marthe, Jungmann, Eva, Rowson, Katie, Castro, Hannah, and Gibb, Diana M.
Subjects: RNA viruses, Male, Maternal Health, Social Sciences, HIV Infections, Pathology and Laboratory Medicine, Adolescents, Condoms, Health Risk Behaviors, Families, Immunodeficiency Viruses, Pregnancy, Risk Factors, Medicine and Health Sciences, Psychology, Public and Occupational Health, Children, Organic Compounds, Obstetrics and Gynecology, Viral Load, Vaccination and Immunization, Chemistry, Contraception, England, Medical Microbiology, Viral Pathogens, Viruses, Physical Sciences, Female, Pathogens, Sexual Health, Research Article, Adolescent, Substance-Related Disorders, Sexual Behavior, Immunology, Microbiology, Young Adult, Retroviruses, Humans, Female Contraception, Papillomavirus Vaccines, Microbial Pathogens, Behavior, Lentivirus, Organic Chemistry, Organisms, Chemical Compounds, Biology and Life Sciences, HIV, Health Care, Age Groups, Adolescent Behavior, Alcohols, People and Places, Quality of Life, Women's Health, Population Groupings, Preventive Medicine, Human Sexual Behavior
Abstract: As adolescents with perinatal HIV (PHIV) survive into adulthood, gaining insight into sexual behaviour and risk-taking is important. Between 2013-2015, 296 PHIV aged 13-21 years and 96 HIV negative affected adolescents (13-23 years) were recruited to the Adolescents and Adults Living with Perinatal HIV (AALPHI) cohort in England. Sexual health data were collected through computer-assisted self-interview questionnaires. Quality of life and household deprivation were also measured. T-tests compared means, and χ2 proportions; logistic regression examined predictors of ever having sex. 120(41%) PHIV and 31(32%) HIV- young people were male, 254(86%) and 70(73%) were black, median age 16 [IQR 15,18] and 16 [14,18] years respectively. 77(26%) PHIV had a previous AIDS diagnosis. 93(32%) PHIV and 38(40%) HIV- had ever had sex; median number of partners was 3 [1,6] and 4 [1,6] respectively. 54 (41%) of 131 young people who were sexually active reported not always using condoms, including 32% (30/93) of PHIV. In multivariable analysis, older age, male sex, worse deprivation score, worse quality of life, and alcohol and/or drugs were associated with ever having sex, but not HIV status. 12/30 PHIV reporting unprotected sex had at least one HIV viral load ≥200c/ml in the previous 12 months. Age at first sex and number of sexual partners were similar among PHIV and HIV-, and comparable to normative data. In conclusion, small numbers of PHIV reported condomless sex with a detectable viral load, which could result in HIV transmission, indicating the need for targeted sexual health and ART adherence interventions for young people with perinatal HIV.
Published: 2018

5. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand : a cohort study

Author: Judd, Ali, Chappell, Elizabeth, Turkova, Anna, Le Coeur, Sophie, Noguera-Julian, Antoni, Goetghebuer, Tessa, Doerholt, Katja, Galli, Luisa, Pajkrt, Dasja, Marques, Laura, Collins, Intira J., Gibb, Diana M., González Tome, Maria Isabel, Navarro, Marisa, Warszawski, Josiane, Königs, Christoph, Spoulou, Vana, Prata, Filipa, Chiappini, Elena, Naver, Lars, Giaquinto, Carlo, Thorne, Claire, Marczynska, Magdalena, Okhonskaia, Liubov, Posfay-Barbe, Klara, Ounchanum, Pradthana, Techakunakorn, Pornchai, Kiseleva, Galina, Malyuta, Ruslan, Volokha, Alla, Ene, Luminita, Goodall, Ruth, Deeks, Steven G., The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord, AII - Infectious diseases, ARD - Amsterdam Reproduction and Development, Paediatric Infectious Diseases / Rheumatology / Immunology, AII - Amsterdam institute for Infection and Immunity, and Institut national d'études démographiques (INED)
Subjects: RNA viruses, Viral Diseases, [SDV]Life Sciences [q-bio], HIV Infections, Infant mortality, Pathology and Laboratory Medicine, Adolescents, Geographical Locations, Cohort Studies, Families, Immunodeficiency Viruses, Risk Factors, Medicine and Health Sciences, Public and Occupational Health, Child, Children, ddc:618, Medicine (all), virus diseases, Viral Load, Thailand, Vaccination and Immunization, AIDS, Europe, Infectious Diseases, Anti-Retroviral Agents, Medical Microbiology, Viral Pathogens, Child, Preschool, Viruses, Disease Progression, Drug Therapy, Combination, Pathogens, Research Article, Adolescent, Death Rates, Biochimie, Immunology, Biotechnologie, Antiretroviral Therapy, [SHS.DEMO]Humanities and Social Sciences/Demography, Microbiology, Immune Suppression, Acquired Immunodeficiency Syndrome, Humans, Infant, Infant, Newborn, Signs and Symptoms, Population Metrics, Antiviral Therapy, Diagnostic Medicine, Virology, Retroviruses, VIH (Virus), ddc:610, Mortality, Microbial Pathogens, Population Biology, HIV (Viruses), Lentivirus, Organisms, Biology and Life Sciences, Biologie moléculaire, HIV, Age Groups, People and Places, Population Groupings, Biologie cellulaire, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Preventive Medicine, Viral Transmission and Infection, Mortalitat infantil
Abstract: Background: Published estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries, including some in Western and Central Europe (W&CE), Eastern Europe (Russia and Ukraine), and Thailand. Methods and findings: Children with perinatal HIV aged 6 months of cART) death and progression to AIDS were assessed. Of 3,526 children included, 32% were from the United Kingdom or Ireland, 30% from elsewhere in W&CE, 18% from Russia or Ukraine, and 20% from Thailand. At cART initiation, median age was 5.2 (IQR 1.4–9.3) years; 35% of children aged 400 c/mL predicted late death. Predictors of early and late progression to AIDS were similar. Study limitations include incomplete recording of US Centers for Disease Control (CDC) disease stage B events and serious adverse events in some countries; events that were distributed over a long time period, and that we lacked power to analyse trends in patterns and causes of death over time. Conclusions: In our study, 3,526 children and adolescents with perinatal HIV infection initiated antiretroviral therapy (ART) in countries in Europe and Thailand. We observed that over 40% of deaths occurred ≤6 months after cART initiation. Greater early mortality risk in infants, as compared to older children, and in Russia, Ukraine, or Thailand as compared to W&CE, raises concern. Current severe immune suppression, being underweight, and unsuppressed viral load were associated with a higher risk of death at >6 months after initiation of cART., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2018
Full Text: View/download PDF

6. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

Author: Monge, S., Mocroft, A., Sabin, A., Touloumi, G., Sighem, A., Abgrall, S., Dray-Spira, R., Spire, B., Castagna, A., Mussini, C., Zangerle, R., Hessamfar, M., Anderson, J., Hamouda, O., Ehren, K., Obel, N., Kirk, O., Antinori, A., Girardi, E., Saracino, A., Calmy, A., Wit, S., Wittkop, L., Bucher, C., Montoliu, A., Raben, D., Prins, M., Meyer, L., Chene, G., Burns, F., Amo, J., Judd, Ali, Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle, Ghosn, Jade, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Fätkenheuer, Gerd, Amo, Julia, Obel, Niels, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pérez-Hoyos, Santiago, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera-Julian, Antoni, Antinori, Andrea, Monforte, Antonella, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo, Soriano-Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miró, Josem, Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Torti, Carlo, Sabin, Caroline, Teira, Ramon, Garrido, Myriam, Haerry, David, Wit, Stéphane, Miró, M., Costagliola, Dominique, d'Arminio-Monforte, Antonella, Raben, Dorthe, Chêne, Geneviève, Barger, Diana, Schwimmer, Christine, Termote, Monique, Campbell, Maria, Frederiksen, Casper M, Friis-Møller, Nina, Kjaer, Jesper, Brandt, Rikke, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Cozzi-Lepri, Alessandro, Davies, Mary-Anne, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Grabar, Sophie, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Miró, Jose, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Rohner, Eliane, Schomaker, Michael, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Valk, Marc, Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in, Eurocoord, Castagna, Antonella, AII - Infectious diseases, APH - Global Health, Infectious diseases, APH - Aging & Later Life, Global Health, Monge, S, Mocroft, A, Sabin, A, Touloumi, G, Sighem, A, Abgrall, S, Dray-Spira, R, Spire, B, Castagna, A, Mussini, C, Zangerle, R, Hessamfar, M, Anderson, J, Hamouda, O, Ehren, K, Obel, N, Kirk, O, Antinori, A, Girardi, E, Saracino, A, Calmy, A, Wit, S, Wittkop, L, Bucher, C, Montoliu, A, Raben, D, Prins, M, Meyer, L, Chene, G, Burns, F, Amo, J, Judd, A, Warszawski, J, Dabis, F, Krause, M, Ghosn, J, Leport, C, Reiss, P, Wit, F, Bucher, H, Gibb, D, Fatkenheuer, G, Thorne, C, Stephan, C, Perez-Hoyos, S, Bartmeyer, B, Chkhartishvili, N, Noguera-Julian, A, Monforte, A, Brockmeyer, N, Prieto, L, Conejo, P, Soriano-Arandes, A, Battegay, M, Kouyos, R, Tookey, P, Casabona, J, Miro, J, Konopnick, D, Goetghebuer, T, Sonnerborg, A, Torti, C, Sabin, C, Teira, R, Garrido, M, Haerry, D, Miro, M, Costagliola, D, d'Arminio-Monforte, A, Barger, D, Schwimmer, C, Termote, M, Campbell, M, Frederiksen, C, Friis-Moller, N, Kjaer, J, Brandt, R, Berenguer, J, Bohlius, J, Bouteloup, V, Cozzi-Lepri, A, Davies, M, Dorrucci, M, Dunn, D, Egger, M, Furrer, H, Guiguet, M, Grabar, S, Lambotte, O, Leroy, V, Lodi, S, Matheron, S, Nakagawa, F, Paredes, R, Phillips, A, Puoti, M, Rohner, E, Schomaker, M, Smit, C, Sterne, J, Thiebaut, R, and Valk, M
Subjects: Male, 0301 basic medicine, Latin Americans, HIV Infections, migrants, Anti-Retroviral Agents/therapeutic use, Cohort Studies, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Epidemiology, Pharmacology (medical), 030212 general & internal medicine, Immunovirological response, Young adult, ddc:616, Transients and Migrants, Health Policy, virus diseases, Middle Aged, Viral Load, 3. Good health, Europe, combination antiretroviral therapy, HIV, immunovirological response, sex, Infectious Diseases, Treatment Outcome, Anti-Retroviral Agents, RNA, Viral, Female, Sex, Viral load, Cohort study, Adult, Cart, Combination antiretroviral therapy, medicine.medical_specialty, Adolescent, HIV Infections/drug therapy, Young Adult, 03 medical and health sciences, Population Groups, medicine, Humans, RNA, Viral/blood, Aged, business.industry, Migrant, 030112 virology, Confidence interval, CD4 Lymphocyte Count, migrant, Institutional repository, Immunology, business, Demography
Abstract: Objectives: The aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004-2013. Methods: Migrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), Caribbean (CRB) and Asia/Oceania (ASIA/OCE). Native (NAT) individuals were defined as those originating from the reporting country. CD4 cell counts were modelled using piecewise linear mixed-effects models with two slopes, whereas models to estimate subdistribution hazard ratios (sHRs) were used for time to virological response (VR) (i.e. time from cART initiation to the first of two successive HIV RNA measurements < 400 HIV-1 RNA copies/ml). Results: Of 32 817 individuals, 25 799 (78.6%) were men. The percentage of migrants was higher in women (48.9%) than in men (21.2%) and migrants from SSA accounted for the largest migrant group (29.9% in men and 63.3% in women). Migrant men and women from SSA started at lower CD4 cell counts than NAT individuals, which remained lower over time. VR was â¥ 85% at 12 months for all groups except CRB women (77.7%). Compared with NAT men and women, lower VR was experienced by NAME [sHR 0.91; 95% confidence interval (CI) 0.86-0.97] and SSA (sHR 0.88; 95% CI 0.82-0.95) men and CRB (sHR 0.77; 85% CI 0.67-0.89) women, respectively. Conclusions: Immunovirological response to cART in Western Europe varies by GO and sex of patients. ART benefits are not equal for all, underlining the point that efforts need to prioritize those most in need.
Published: 2018

7. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study

Author: Wang, Qing, De Luca, Andrea, Smith, Colette, Zangerle, Robert, Sambatakou, Helen, Bonnet, Fabrice, Smit, Colette, Schommers, Philipp, Thornton, Alicia, Berenguer, Juan, Peters, Lars, Spagnuolo, Vincenzo, Ammassari, Adriana, Antinori, Andrea, Roldan, Eugenia Quiros, Mussini, Cristina, Miro, Jose M., Konopnicki, Deborah, Fehr, Jan, Campbell, Maria A., Termote, Monique, Bucher, Heiner C., De Wit, Stéphane, Costagliola, Dominique, D'Arminio-Monforte, Antonella, Castagna, Antonella, Del Amo, Julia, Mocroft, Amanda, Raben, Dorthe, Chêne, Geneviève, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle Mary, Ghosn, Jade, Leport, Catherine, Wittkop, Linda, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Sabin, Caroline, Gibb, Diana, Fätkenheuer, Gerd, Obel, Niels, Thorne, Claire, Kirk, Ole, Stephan, Christoph, Pérez-Hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera-Julian, Antoni, D'Arminio Monforte, Antonella, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo Rojo, Soriano-Arandes, Antoni, Battegay, Manuel, Rauch, Andri, Tookey, Pat, Casabona, Jordi, Goetghebuer, Tessa, Sönnerborg, Anders, Torti, Carlo, Teira, Ramon, Garrido, Myriam, Haerry, David, Bohlius, Julia, Bouteloup, Vincent, Cozzi-Lepri, Alessandro, Davies, Mary-Anne, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Grabar, Sophie, Judd, Ali, Lambotte, Olivier, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Schomaker, Michael, Sterne, Jonathan, Thiebaut, Rodolphe, Van Der Valk, Marc, Wyss, Natasha, Barger, Diana, Schwimmer, Christine, Friis-Møller, Nina, Kjaer, Jesper, Brandt, Rikke Salbøl, Wang, Q, De Luca, A, Smith, C, Zangerle, R, Sambatakou, H, Bonnet, F, Smit, C, Schommers, P, Thornton, A, Berenguer, J, Peters, L, Spagnuolo, V, Ammassari, A, Antinori, A, Roldan, E, Mussini, C, Miro, J, Konopnicki, D, Fehr, J, Campbell, M, Termote, M, Bucher, H, Puoti, M, University of Zurich, Bucher, Heiner C, Quiros Roldan, E, Miro, Jm, Campbell, Ma, Bucher, Hc, on behalf of The Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in, Eurocoord, and Castagna, Antonella
Subjects: Male, Lymphoma, Hepatitis B Surface Antigen, HIV Infections, medicine.disease_cause, Cohort Studies, 10234 Clinic for Infectious Diseases, 0302 clinical medicine, Risk Factors, HIV Infection, 030212 general & internal medicine, Viral, Chronic, media_common, Incidence (epidemiology), Hepatitis B Core Antigen, Lymphoma, Non-Hodgkin, Hazard ratio, virus diseases, General Medicine, Hepatitis C, Hepatitis B, Hepatitis B Core Antigens, Hepatitis Antibodie, 030220 oncology & carcinogenesis, RNA, Viral, Female, hepatitis c and b, Cohort study, Human, Adult, medicine.medical_specialty, Anti-HIV Agents, Biomarkers, Hepatitis Antibodies, Hepatitis B Surface Antigens, Hepatitis B, Chronic, Hepatitis C, Chronic, Humans, Immunoglobulin G, Hepatitis C virus, Non-Hodgkin, 610 Medicine & health, Settore MED/17 - MALATTIE INFETTIVE, 03 medical and health sciences, Internal medicine, Internal Medicine, medicine, media_common.cataloged_instance, HIV HCV NHL HBV, European union, Hepatitis B virus, business.industry, Risk Factor, Anti-HIV Agent, Biomarker, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), medicine.disease, digestive system diseases, 2724 Internal Medicine, Immunology, RNA, Cohort Studie, business
Abstract: Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear. Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients. Design: Cohort study. Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available. Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring. Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients. Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group. Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL. Primary Funding Source: European Union Seventh Framework Programme.
Published: 2017

8. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

Author: Chereau, Fanny, Madec, Yoann, Sabin, Caroline, Obel, Niels, Ruiz-Mateos, Ezequiel, Chrysos, Georgios, Fidler, Sarah, Lehmann, Clara, Zangerle, Robert, Wittkop, Linda, Reiss, Peter, Hamouda, Osamah, Perez, Vicente Estrada, Leal, Manuel, Mocroft, Amanda, De Olalla, Patricia Garcia, Ammassari, Adriana, Monforte, Antonella D'Arminio, Mussini, Cristina, Segura, Ferran, Castagna, Antonella, Cavassini, Matthias, Grabar, Sophie, Morlat, Philippe, De Wit, Stéphane, Lambotte, Olivier, Meyer, Laurence, Judd, Ali, Touloumi, Giota, Warszawski, Josiane, Dabis, François, Krause, Murielle Mary, Ghosn, Jade, Leport, Catherine, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Gibb, Diana, Fätkenheuer, Gerd, Del Amo, Julia, Thorne, Claire, Kirk, Ole, Stephan, Christoph, Pérez-Hoyos, Santiago, Bartmeyer, Barbara, Chkhartishvili, Nikoloz, Noguera-Julian, Antoni, Antinori, Andrea, Brockmeyer, Norbert, Prieto, Luis, Conejo, Pablo Rojo, Soriano-Arandes, Antoni, Battegay, Manuel, Kouyos, Roger, Tookey, Pat, Casabona, Jordi, Miró, Jose M., Konopnick, Deborah, Goetghebuer, Tessa, Sönnerborg, Anders, Torti, Carlo, Teira, Ramon, Garrido, Myriam, Haerry, David, Miró, Jose Ma, Costagliola, Dominique, D'Arminio-Monforte, Antonella, Raben, Dorthe, Chêne, Geneviève, Barger, Diana, Schwimmer, Christine, Termote, Monique, Campbell, Maria, Frederiksen, Casper M., Friis-Møller, Nina, Kjaer, Jesper, Brandt, Rikke Salbøl, Berenguer, Juan, Bohlius, Julia, Bouteloup, Vincent, Cozzi-Lepri, Alessandro, Davies, Mary-Anne, Dorrucci, Maria, Dunn, David, Egger, Matthias, Furrer, Hansjakob, Guiguet, Marguerite, Leroy, Valériane, Lodi, Sara, Matheron, Sophie, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Rohner, Eliane, Schomaker, Michael, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Van Der Valk, Marc, Fanny, C, Yoann, M, Caroline, S, Niels, O, Ezequiel, R, Georgios, C, Sarah, F, Clara, L, Robert, Z, Linda, W, Peter, R, Osamah, H, Vicente Estrada, P, Manuel, L, Amanda, M, Patricia Garcia De, O, Adriana, A, Antonella D’Arminio, M, Cristina, M, Ferran, S, Antonella, C, Matthias, C, Sophie, G, Philippe, M, Stéphane De, W, Olivier, L, Laurence, M, Puoti, M, Chereau, F, Madec, Y, Sabin, C, Obel, N, Ruiz-Mateos, E, Chrysos, G, Fidler, S, Lehmann, C, Zangerle, R, Wittkop, L, Reiss, P, Hamouda, O, Perez, Ve, Leal, M, Mocroft, A, De Olalla, Pg, Ammassari, A, Monforte, Ada, Mussini, C, Segura, F, Castagna, A, Cavassini, M, Grabar, S, Morlat, P, De Wit, S, Lambotte, O, Meyer, L, The HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in, Eurocoord, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (France), HIV Monitoring Foundation, Augustinus Foundation, European Commission, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology, Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), University College London Hospitals (UCLH), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Hospital Universitario Virgen del Rocío [Sevilla], Tzaneio General Hospital, Imperial College London, German Center for Infection Research - Partner Site Bonn-Cologne (DZIF), Universität Innsbruck [Innsbruck], Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Robert Koch Institute [Berlin] (RKI), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), CIBER de Epidemiología y Salud Pública (CIBERESP), Istituto Nazionale di Malattie Infettive 'Lazzaro Spallanzani' (INMI), University of Milan, Università degli Studi di Modena e Reggio Emilia (UNIMORE), Hospital Universitari Parc Taulí of Sabadell, Barcelona, Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Université de Lausanne (UNIL), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université libre de Bruxelles (ULB), Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), Università degli Studi di Milano = University of Milan (UNIMI), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Université de Lausanne = University of Lausanne (UNIL), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), HAL UPMC, Gestionnaire, AII - Infectious diseases, APH - Aging & Later Life, Global Health, Amsterdam institute for Infection and Immunity, HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD, Imperial College Healthcare NHS Trust- BRC Funding, and Medical Research Council (MRC)
Subjects: Male, HIV Infections, CD8-Positive T-Lymphocytes, Pathology and Laboratory Medicine, Immunodeficiency Viruses, HIV-1/immunology, Public and Occupational Health, lcsh:Science, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Female, HIV-1, Humans, Viral Load, Viremia, Virus Replication, Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all), virus diseases, CD8-Positive T-Lymphocytes/drug effects, Antiretroviral Therapy, Highly Active/methods, Medical Microbiology, Viral Pathogens, Science & Technology - Other Topics, Human, Blood cells, Immunology, HIV Infections/drug therapy, Virus Replication/immunology, Men WHO Have Sex with Men, Cytotoxic T cells, Microbiology, Viremia/drug therapy, Microbial Pathogens, Science & Technology, lcsh:R, Organisms, Biology and Life Sciences, Anti-HIV Agent, NATURAL-HISTORY, CD8-Positive T-Lymphocyte, Anti-HIV Agents/therapeutic use, HIV CD4 AIDS, T-CELLS, Population Groupings, lcsh:Q, Preventive Medicine, Sexuality Groupings, RNA viruses, RNA LEVELS, lcsh:Medicine, PROGRESSION, ACTIVATION, INFECTION, Cellular types, Medicine and Health Sciences, HIV Infection, Medicine (all), Immune cells, HIV diagnosis and management, ABSENCE, Vaccination and Immunization, Multidisciplinary Sciences, Infectious Diseases, CD4-Positive T-Lymphocyte, Viruses, White blood cells, Pathogens, Research Article, Cell biology, Evolutionary Immunology, Infectious Disease Control, General Science & Technology, T cells, Antiretroviral Therapy, CD4-Positive T-Lymphocytes/drug effects, CD4 Lymphocyte Count/methods, Viral Evolution, Antiviral Therapy, Virology, MD Multidisciplinary, Retroviruses, Evolutionary Biology, Lentivirus, HIV, Viral Load/drug effects, Diagnostic medicine, Organismal Evolution, Animal cells, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, REPLICATION, People and Places, Microbial Evolution, CD4-Positive T-Lymphocytes/immunology, CD4-Positive T-Lymphocytes/virology, CD8-Positive T-Lymphocytes/immunology, HIV Infections/immunology, HIV Infections/virology, Viral Load/immunology, Viremia/immunology, Viremia/virology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, INVERSE PROBABILITY
Abstract: [Objective] HIV controllers (HICs) spontaneously maintain HIV viral replication at low level without antiretroviral therapy (ART), a small number of whom will eventually lose this ability to control HIV viremia. The objective was to identify factors associated with loss of virological control., [Methods] HICs were identified in COHERE on the basis of ≥5 consecutive viral loads (VL) ≤500 copies/mL over ≥1 year whilst ART-naive, with the last VL ≤500 copies/mL measured ≥5 years after HIV diagnosis. Loss of virological control was defined as 2 consecutive VL >2000 copies/mL. Duration of HIV control was described using cumulative incidence method, considering loss of virological control, ART initiation and death during virological control as competing outcomes. Factors associated with loss of virological control were identified using Cox models. CD4 and CD8 dynamics were described using mixed-effect linear models., [Results] We identified 1067 HICs; 86 lost virological control, 293 initiated ART, and 13 died during virological control. Six years after confirmation of HIC status, the probability of losing virological control, initiating ART and dying were 13%, 37%, and 2%. Current lower CD4/CD8 ratio and a history of transient viral rebounds were associated with an increased risk of losing virological control. CD4 declined and CD8 increased before loss of virological control, and before viral rebounds., [Discussion] Expansion of CD8 and decline of CD4 during HIV control may result from repeated low-level viremia. Our findings suggest that in addition to superinfection, other mechanisms, such as low grade viral replication, can lead to loss of virological control in HICs., The COHERE study group has received unrestricted funding from: Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), France; HIV Monitoring Foundation, The Netherlands; and the Augustinus Foundation, Denmark. The research leading to these results received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n° 260694.
Published: 2017
Full Text: View/download PDF

9. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord

Author: Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, Franã§ois, Krause, Murielle Mary, Ghosn, Jade, Leport, Catherine, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Sabin, Caroline, Gibb, Diana, Fã¤tkenheuer, Gerd, Del Amo, Julia, Obel, Niels, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pã©rez hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Noguera julian, Antoni, Antinori, Andrea, D'arminio monforte, Antonella, Brockmeyer, Norbert, Ramos, Josã, Conejo, Pablo Rojo, Soriano, Toni, Battegay, Manuel, Rauch, Andri, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Mirã², Jose M., Konopnick, Deborah, Goetghebuer, Tessa, Torti, Carlo, Teira, Ramon, Garrido, Myriam, Haerry, David, De Wit, Stã©phane, Costagliola, Dominique, Grarup, Jesper, Chãªne, Genevieve, Cohort, Paediatric, Judd, Ali, Bohlius, Julia, Bouteloup, Vincent, Cozzi lepri, Alessandro, Dorrucci, Maria, Egger, Matthias, Engsig, Frederik, Furrer, Hansjakob, Lambotte, Olivier, Lodi, Sara, Matheron, Sophie, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Van Der Valk, Marc, Wittkop, Linda, Wyss, Natasha, CASTAGNA, ANTONELLA, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Infectious diseases, Zangerle, Robert, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, Franã§oi, Krause, Murielle Mary, Ghosn, Jade, Leport, Catherine, Reiss, Peter, Wit, Ferdinand, Prins, Maria, Bucher, Heiner, Sabin, Caroline, Gibb, Diana, Fã¤tkenheuer, Gerd, Del Amo, Julia, Obel, Niel, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Stephan, Christoph, Pã©rez hoyos, Santiago, Hamouda, Osamah, Bartmeyer, Barbara, Noguera julian, Antoni, Antinori, Andrea, D'arminio monforte, Antonella, Brockmeyer, Norbert, Ramos, Josã, Conejo, Pablo Rojo, Soriano, Toni, Battegay, Manuel, Rauch, Andri, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Mirã², Jose M., Castagna, Antonella, Konopnick, Deborah, Goetghebuer, Tessa, Torti, Carlo, Teira, Ramon, Garrido, Myriam, Haerry, David, De Wit, Stã©phane, Costagliola, Dominique, Grarup, Jesper, Chãªne, Genevieve, Cohort, Paediatric, Judd, Ali, Bohlius, Julia, Bouteloup, Vincent, Cozzi lepri, Alessandro, Dorrucci, Maria, Egger, Matthia, Engsig, Frederik, Furrer, Hansjakob, Lambotte, Olivier, Lodi, Sara, Matheron, Sophie, Monge, Susana, Nakagawa, Fumiyo, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Van Der Valk, Marc, Wittkop, Linda, and Wyss, Natasha
Subjects: Adult, Male, Cart, Health Knowledge, Attitudes, Practice, Pediatrics, medicine.medical_specialty, Delayed Diagnosis, Higher education, Immunology, HIV Infections, 610 Medicine & health, Socioeconomic Factor, Logistic regression, Education, Cohort Studies, Acquired immunodeficiency syndrome (AIDS), 360 Social problems & social services, Late diagnosi, medicine, Humans, Immunology and Allergy, HIV Infection, business.industry, Delayed Diagnosi, International Standard Classification of Education, Hiv, Odds ratio, Patient Acceptance of Health Care, medicine.disease, Confidence interval, Antiretroviral therapy, CD4 Lymphocyte Count, Europe, Infectious Diseases, Anti-Retroviral Agents, Socioeconomic Factors, Socioeconomic inequitie, Anti-Retroviral Agent, Cohort Studie, business, Human, Cohort study
Abstract: OBJECTIVES In Europe and elsewhere, health inequalities among HIV-positive individuals are of concern. We investigated late HIV diagnosis and late initiation of combination antiretroviral therapy (cART) by educational level, a proxy of socioeconomic position. DESIGN AND METHODS We used data from nine HIV cohorts within COHERE in Austria, France, Greece, Italy, Spain and Switzerland, collecting data on level of education in categories of the UNESCO/International Standard Classification of Education standard classification: non-completed basic, basic, secondary and tertiary education. We included individuals diagnosed with HIV between 1996 and 2011, aged at least 16 years, with known educational level and at least one CD4 cell count within 6 months of HIV diagnosis. We examined trends by education level in presentation with advanced HIV disease (AHD) (CD4
Published: 2014
Full Text: View/download PDF

10. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children. A EuroCoord-CHAIN-EPPICC Joint project

Author: Ngo-Giang-Huong, Nicole, Ene, Luminita, Ramos, José Tomás, Cellerai, Cristina, Klimkait, Thomas, Brichard, Bénédicte, Valerius, Niels, Sabin, Caroline, Teira, Ramón, Obel, Niels, Stephan, Christoph, Wittkop, Linda, De Wit, Stéphane, Thorne, Claire, Gibb, Diana, Schwimmer, Christine, Campbell, Maria Athena, Pillay, Deenan, Lallemant, Marc, Rosenfeldt, Vibeke, Dabis, François, Judd, Ali, Reiss, Peter, Goetghebuer, Tessa, Duiculescu, Dan, Noguera-Julian, Antoni, Marczynska, Magdalena, Giacquinto, Carlo, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Global Health, EuroCoord-CHAIN-EPPICC joint project study group, and The EuroCoord-CHAIN-EPPICC joint project study group
Subjects: 0301 basic medicine, Male, endocrine system diseases, First-line combination antiretroviral therapy, HIV Infections, Drug resistance, Kaplan-Meier Estimate, Adolescent, Anti-HIV Agents/therapeutic use, CD4 Lymphocyte Count, Child, Child, Preschool, Drug Resistance, Viral/drug effects, Drug Resistance, Viral/genetics, Drug Therapy, Combination, Female, HIV Infections/drug therapy, HIV Infections/mortality, HIV Infections/virology, HIV-1/drug effects, Humans, Infant, Mutation, Reverse Transcriptase Inhibitors/therapeutic use, Viral Load/drug effects, Children, HIV, Pre-treatment drug resistance mutations, Virological failure, 0302 clinical medicine, Medical microbiology, Interquartile range, immune system diseases, 030212 general & internal medicine, Pathologie maladies infectieuses, virus diseases, Viral Load, 3. Good health, Infectious Diseases, Reverse Transcriptase Inhibitors, Viral load, Research Article, Cart, medicine.medical_specialty, Anti-HIV Agents, 030106 microbiology, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Internal medicine, mental disorders, Drug Resistance, Viral, medicine, lcsh:RC109-216, ddc:610, Proportional hazards model, business.industry, Confidence interval, eye diseases, Regimen, nervous system, Immunology, HIV-1, sense organs, business
Abstract: Background: Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children. Methods: HIV-infected children 500 copies/mL after 6 months cART and was assessed by Cox proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and virology characteristics and calendar period of cART start and initial cART regimen. Results: Of 476 children, 88 % were vertically infected. At cART initiation, median (interquartile range) age was 6.6 years (2.1-10.1), CD4 cell count 297 cells/mm3 (98-639), and HIV-RNA 5.2 log10copies/mL (4.7-5.7). Of 37 children (7.8 %, 95 % confidence interval (CI), 5.5-10.6) harboring a virus with ≥1 PDR mutations, 30 children had a virus resistant to ≥1 of the prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8 % (95 %CI, 16.4-23.9). Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to ≥1 drug prescribed than among those receiving fully active cART: 32.1 % (17.2-54.8) versus 19.4 % (15.9-23.6) (P = 0.095). In multivariable analysis, age was associated with a higher risk of VF with a 12 % reduced risk per additional year (HR 0.88; 95 %CI, 0.82-0.95; P < 0.001). Conclusions: PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk of VF decreased by 12 % per additional year at treatment initiation which may be due to fading of PDR mutations over time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of virological failure., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2016

11. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Author: Mocroft, Amanda, Lundgren, Jens D., Sabin, Miriam Lewis, D'arminio Monforte, Antonella, Brockmeyer, Norbert, Casabona, Jordi, Costagliola, Dominique, Dabis, Francois, De Wit, Stã©phane, Fã¤tkenheuer, Gerd, Furrer, Hansjakob, Johnson, Anne M., Lazanas, Marios K., Leport, Catherine, Moreno, Santiago, Obel, Niels, Post, Frank A., Reekie, Joanne, Reiss, Peter, Sabin, Caroline, Skaletz rorowski, Adriane, Suarez lozano, Ignacio, Torti, Carlo, Warszawski, Josiane, Zangerle, Robert, Fabre colin, Cã©line, Kjaer, Jesper, Chene, Genevieve, Grarup, Jesper, Kirk, Ole, Lundgren, Jens, Sabin, Miriam, Castagna, Antonella, Johnson, Anne, Lazanas, Mario, Suarez loano, Ignacio, Post, Frank, Touloumi, Giota, Meyer, Laurence, Dabis, Franã§ois, Krause, Murielle Mary, Ghosn, Jade, De Wolf, Frank, Prins, Maria, Bucher, Heiner, Gibb, Diana, Hamouda, Osamah, Bartmeyer, Barbara, Del Amo, Julia, Thorne, Claire, Stephan, Christoph, Pã©rez hoyos, Santiago, Noguera julian, Antoni, Antinori, Andrea, Ramos, Josã©, Battegay, Manuel, Rauch, Andri, Mussini, Cristina, Tookey, Pat, Mirã³, Jose M., De Wit, Stephane, Goetghebuer, Tessa, Teira, Ramon, Garrido, Myriam, Judd, Ali, Haerry, David, Weller, Ian, D'arminio monforte, Antonella, Schwimmer, Christine, Termote, Monique, Touzeau, Guillaume, Campbell, Maria, Friis mã¸ller, Nina, Bohlius, Julia, Bouteloup, Vincent, Cozzi lepri, Alessandro, Dorrucci, Maria, Egger, Matthias, Engsig, Frederik, Lambotte, Olivier, Lewden, Charlotte, Lodwick, Rebecca, Matheron, Sophie, Miro, Jose, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Scherrer, Alexandra, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Von Wyl, Viktor, Wittkop, Linda, CASTAGNA, ANTONELLA, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Other departments, Infectious diseases, Mocroft, Amanda, Lundgren, Jens D., Sabin, Miriam Lewi, D'arminio Monforte, Antonella, Brockmeyer, Norbert, Casabona, Jordi, Castagna, Antonella, Costagliola, Dominique, Dabis, Francoi, De Wit, Stã©phane, Fã¤tkenheuer, Gerd, Furrer, Hansjakob, Johnson, Anne M., Lazanas, Marios K., Leport, Catherine, Moreno, Santiago, Obel, Niel, Post, Frank A., Reekie, Joanne, Reiss, Peter, Sabin, Caroline, Skaletz rorowski, Adriane, Suarez lozano, Ignacio, Torti, Carlo, Warszawski, Josiane, Zangerle, Robert, Fabre colin, Cã©line, Kjaer, Jesper, Chene, Genevieve, Grarup, Jesper, Kirk, Ole, Lundgren, Jen, Sabin, Miriam, Johnson, Anne, Lazanas, Mario, Suarez loano, Ignacio, Post, Frank, Touloumi, Giota, Meyer, Laurence, Dabis, Franã§oi, Krause, Murielle Mary, Ghosn, Jade, De Wolf, Frank, Prins, Maria, Bucher, Heiner, Gibb, Diana, Hamouda, Osamah, Bartmeyer, Barbara, Del Amo, Julia, Thorne, Claire, Stephan, Christoph, Pã©rez hoyos, Santiago, Noguera julian, Antoni, Antinori, Andrea, Ramos, Josã©, Battegay, Manuel, Rauch, Andri, Mussini, Cristina, Tookey, Pat, Mirã³, Jose M., De Wit, Stephane, Goetghebuer, Tessa, Teira, Ramon, Garrido, Myriam, Judd, Ali, Haerry, David, Weller, Ian, D'arminio monforte, Antonella, Schwimmer, Christine, Termote, Monique, Touzeau, Guillaume, Campbell, Maria, Friis mã¸ller, Nina, Bohlius, Julia, Bouteloup, Vincent, Cozzi lepri, Alessandro, Dorrucci, Maria, Egger, Matthia, Engsig, Frederik, Lambotte, Olivier, Lewden, Charlotte, Lodwick, Rebecca, Matheron, Sophie, Miro, Jose, Paredes, Roger, Phillips, Andrew, Puoti, Massimo, Scherrer, Alexandra, Smit, Colette, Sterne, Jonathan, Thiebaut, Rodolphe, Von Wyl, Viktor, and Wittkop, Linda
Subjects: Male, Time Factors, Epidemiology, HIV Infections, Substance Abuse, Intravenou, Logistic regression, Rate ratio, Biochemistry, 0302 clinical medicine, Risk Factors, HIV Seropositivity, HIV Infection, 030212 general & internal medicine, Cooperative Behavior, Substance Abuse, Intravenous, 10. No inequality, 0303 health sciences, Incidence, Incidence (epidemiology), General Medicine, Sciences bio-médicales et agricoles, 3. Good health, AIDS, Europe, Substance abuse, Infectious Diseases, Treatment Outcome, Disease Progression, symbols, Medicine, Female, Human, Biotechnology, HIV infections, Research Article, medicine.medical_specialty, Time Factor, Sexually Transmitted Diseases, 610 Medicine & health, Sensitivity and Specificity, 03 medical and health sciences, symbols.namesake, Acquired immunodeficiency syndrome (AIDS), 360 Social problems & social services, Mortalitat, medicine, Humans, Poisson regression, Mortality, Epidemiologia, Molecular Biology, 030306 microbiology, business.industry, Risk Factor, Cell Biology, Odds ratio, medicine.disease, CD4 Lymphocyte Count, Immunology, Infeccions per VIH, business, Demography
Abstract: Amanda Mocroft and colleagues investigate risk factors and health outcomes associated with diagnosis at a late stage of infection in individuals across Europe. Please see later in the article for the Editors' Summary, Background Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. Methods and Findings LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count, Editors' Summary Background Every year about 2.5 million people become newly infected with HIV, the virus that causes AIDS. HIV can be transmitted through unprotected sex with an infected partner, from an HIV-positive mother to her unborn baby, or through injection of drugs. Most people do not become ill immediately after infection with HIV although some develop a short influenza-like illness. The next stage of the HIV infection, which may last up to 10 years, also has no major symptoms but, during this stage, HIV slowly destroys immune system cells, including CD4 cells, a type of lymphocyte. Eventually, when the immune system is unable to fight off infections by other disease-causing organisms, HIV-positive people develop AIDS-defining conditions—unusual viral, bacterial, and fungal infections and unusual tumors. Progression to AIDS occurs when any severe AIDS-defining condition is diagnosed, when the CD4 count in the blood falls below 200 cells/mm3, or when CD4 cells account for fewer than 15% of lymphocytes. Why Was This Study Done? People need to know they are HIV positive as soon as possible after they become infected because antiretroviral therapy, which controls but does not cure HIV infection, works best if it is initiated when people still have a relatively high CD4 count. Early diagnosis also reduces the risk of onward HIV transmission. However, 40%–60% of HIV-positive individuals in developed countries are not diagnosed until they have a low CD4 count or an AIDS-defining illness. Reasons for such late presentation include fear of discrimination or stigmatization, limited knowledge about HIV risk factors, testing, and treatment together with missed opportunities to offer an HIV test. Policy makers involved in national and international HIV control programs need detailed information about patterns of late presentation before they can make informed decisions about how to reduce this problem. In this study, therefore, the researchers use data collected by the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) to analyze trends in late presentation over time across Europe and in different groups of people at risk of HIV infection and to investigate the clinical consequences of late presentation. What Did the Researchers Do and Find? The researchers analyzed data collected from 84,524 individuals participating in more than 20 observational studies that were undertaken in 35 European countries and that investigated outcomes among HIV-positive people. Nearly 54% of the participants were late presenters—individuals who had a CD4 count of less than 350 cells/mm3 or an AIDS-defining illness within 6 months of HIV diagnosis. Late presentation was highest among heterosexual males, in Southern European countries, and among people originating in Africa. Overall, late presentation decreased from 57.3% in 2000 to 51.7% in 2010/11. However, whereas late presentation decreased over time among men having sex with men in Central and Northern Europe, for example, it increased over time among female heterosexuals in Southern Europe. Finally, among the 8,000 individuals who developed a new AIDS-defining illness or died during follow-up, compared to non-late presentation, late presentation was associated with an increased incidence of AIDS/death in all regions of Europe during the first and second year after HIV diagnosis (but not in later years); the largest increase in incidence (13-fold) occurred during the first year after diagnosis in Southern Europe. What Do These Findings Mean? These findings indicate that, although late presentation with HIV infection has decreased in recent years, it remains an important issue across Europe and in all groups of people at risk of HIV infection. They also show that individuals presenting late have a worse clinical outlook, particularly in the first and second year after diagnosis compared to non-late presenters. Several aspects of the study design may affect the accuracy and usefulness of these findings, however. For example, some of the study participants recorded as late presenters may have been people who were aware of their HIV status but who chose not to seek care for HIV infection, or may have been seen in the health care system prior to HIV diagnosis without being offered an HIV test. Delayed entry into care and late presentation are likely to have different risk factors, a possibility that needs to be studied further. Despite this and other study limitations, these findings nevertheless suggest that HIV testing strategies that encourage early testing in all populations at risk, that ensure timely referrals, and that improve retention in care are required to further reduce the incidence of late presentation with HIV infection in Europe. Additional Information Please access these websites via the online version of this summary at http://dx.doi.org/ 10.1371/journal.pmed.1001510. Information is available from the US National Institute of Allergy and infectious diseases on HIV infection and AIDS NAM/aidsmap provides basic information about HIV/AIDS, and summaries of recent research findings on HIV care and treatment Information is available from Avert, an international AIDS charity, on many aspects of HIV/AIDS, including detailed information on the stages of HIV infection and on HIV and AIDS in Europe (in English and Spanish) The HIV in Europe Initiative has information about strategies to improve earlier diagnosis and access to care in Europe Information about COHERE, which was established in 2005 to conduct epidemiological research on the prognosis and outcome of HIV-infected people from across Europe, is available; more information on the consensus definition of late presentation used in this study is available through the HIV in Europe initiative Patient stories about living with HIV/AIDS are available through Avert and through the nonprofit website Healthtalkonline
Published: 2013
Full Text: View/download PDF

12. Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.

Author: Innes, Steve, Harvey, Justin, Collins, Intira Jeannie, Cotton, Mark Fredric, and Judd, Ali
Subjects: ANTIRETROVIRAL agents, HIV infections, THERAPEUTICS, JUVENILE diseases, ENZYME inhibitors, PREVENTIVE medicine
Abstract: Background: Following widespread use of stavudine, a thymidine analogue, in antiretroviral therapy (ART) over the past three decades, up to a third of children developed lipoatrophy (LA) and/or lipohypertrophy (LH). Following phasing-out of stavudine, incidence of newly-diagnosed LA and LH declined dramatically. However, the natural history of existing cases should be explored, particularly with prolonged protease inhibitor exposure. Methods: The Collaborative HIV Paediatric Study (CHIPS) is a multicentre cohort study of most HIV-infected children in the United Kingdom and Ireland. Those on ART with a LA/LH assessment recorded in 2003–2011 were included. Assessments were completed annually by consultant physicians. Using the 0–3 grading system, LA or LH was defined as grade 2 or 3. Resolution was defined as return to grade 1 or 0 in all body regions. Results: Of 1345 children followed for median (IQR) 5.5 (2.9, 8.2) years after ART initiation, 30 developed LA and 27 developed LH, all at least 2 years after ART initiation. Median age at LA diagnosis was 11 (10, 13) years and at LH diagnosis was 13 (11, 15) years. Children with LA were more likely white (p<0.0001); lower height-for-age z-score at ART initiation (p = 0.02); initiated ART earlier (p = 0.04), with longer ART exposure (p = 0.04). Children with LH were similar to those without. Analysis of individual drugs revealed that LA was associated with greater duration of exposure to stavudine and didanosine; while LH was associated with greater duration of exposure to stavudine and ritonavir (given alone or in combination with another protease inhibitor). Median time in follow-up following ART switch was 2.8 (1.9, 4.9) and 2.5 (1.6, 4.7) years respectively. Resolution occurred in 10 (30%) of LA cases (median time to resolution 2.3 [1.8, 3.6] years) and 3 (11%) of LH cases (median time to resolution 2.0 [1.7, 2.1] years). Conclusions: Prevalence of LA and LH were low, with some resolution noted, especially for LA. More long-term data are needed. [ABSTRACT FROM AUTHOR]
Published: 2018
Full Text: View/download PDF

13. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

Author: Bohlius, Julia, Schmidlin, Kurt, Costagliola, Dominique, Fätkenheuer, Gerd, May, Margaret, Murillo, Ana Maria Caro, Mocroft, Amanda, Bonnet, Fabrice, Clifford, Gary, Touloumi, Giota, Miro, Jose M., Chene, Genevieve, Lundgren, Jens, Egger, Matthias, Antinori, Andrea, Boué, François, Brockmeyer, Norbert, Casabona, Jordi, Lopez-Guillermo, Armando, Ribera, Josep Maria, Dronda, Fernando, Obel, Niels, Fisher, Martin, Franceschi, Silvia, Gibb, Diana, Le Moing, Vincent, Nadal, David, Prins, Maria, Raffi, François, Roca, Bernardino, Verbon, Annelies, Wolf, Timo, Fortuny, Claudia, Chakraborty, Rana, Minder, Christoph, Sterne, Jonathan, Zwahlen, Marcel, Ellefson, Michelle, Kjaer, Jesper, Collin, Fidéline, Colin, Céline, Weller, Ian, Ledergerber, Bruno, Warszawski, Josiane, Meyer, Laurence, Dabis, François, Krause, Murielle Mary, Goujard, Cecile, Leport, Catherine, de Wolf, Frank, Reiss, Peter, Porter, Kholoud, Dorrucci, Maria, Sabin, Caroline, Del Amo, Julia, Thorne, Claire, Kirk, Ole, Staszewski, Schlomo, Perez-Hoyos, Santiago, Almeda, Jesus, D'Arminio Monforte, Antonella, de Martino, Maurizio, Ramos, Jose, Battegay, Manuel, Mussini, Cristina, Tookey, Pat, Castagna, Antonella, de Wit, Stephane, Torti, Carlo, Teira, Ramon, Garrido, Myriam, Dedes, Nikos, Phillips, Andrew, Furrer, Hansjakob, Newell, Marie Louise, Telenti, Amalio, Pantazis, Nikos, Lechenadec, Jérôme, Boufassa, Faroudy, Tran, Laurent, Balestre, Eric, Lanoy, Emilie, Couturier, Françoise, Rispens, Theo, Gras, Luuk A.J., Bhaskaran, Krishnan, Hill, Teresa, Judd, Ali, Duong, Trinh, Sobrino, Paz, Jennings, Beverley, Bonfigli, Sandro, Cozzi-Lepri, Alessandro, Corvasce, Stefano, Adorni, Fulvio, Ridolfo, Anna Lisa, Paraninfo, Giuseppe, Keiser, Olivia, Borghi, Vanni, Weller, Ian, Costagliola, Dominique, Ledergerber, Bruno, Lundgren, Jen, Chene, Genevieve, Touloumi, Giota, Warszawski, Josiane, Meyer, Laurence, Dabis, Francoi, Krause Murielle, Mary, Leport, Catherine, de Wolf, Frank, Reiss, Peter, Porter, Kholoud, Dorrucci, Maria, Sabin, Caroline, Gibb, Diana, Del Amo, Julia, Obel, Niel, Thorne, Claire, Mocroft, Amanda, Kirk, Ole, Staszewski, Schlomo, Perez Hoyos, Santiago, Almeda, Jesu, Antinori, Andrea, Monforte A., D'Arminio, de Martino, Maurizio, Brockmeyer, Norbert, Faetkenheuer, Gerd, Ramos, Jose, Battegay, Manuel, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miro Jose, M., Castagna, Antonella, de Wit, Stephane, Torti, Carlo, Teira, Ramon, Garrido, Myriam, Dedes, Niko, Phillips, Andrew, Furrer, Hansjakob, Egger, Matthia, Newell Marie, Louise, Sterne, Jonathan, Telenti, Amalio, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Infectious diseases
Subjects: Cart, Adult, Male, medicine.medical_specialty, Adolescent, Immunology, AIDS-related lymphoma, Young Adult, immune system diseases, Internal medicine, hemic and lymphatic diseases, Antiretroviral Therapy, Highly Active, Epidemiology, medicine, Immunology and Allergy, Humans, Young adult, Mortality, Prospective cohort study, Collaborative study, Immunodeficiency, Non-Hodgkin lymphoma, Lymphoma, AIDS-Related, business.industry, Lymphoma, Non-Hodgkin, Middle Aged, medicine.disease, Prognosis, Surgery, Lymphoma, Antiretroviral therapy, CD4 Lymphocyte Count, Europe, Infectious Diseases, Treatment Outcome, HIV-1, Cohort studies, Female, business, Epidemiologic Methods, Cohort study
Abstract: Objective: We examined survival and prognostic factors of patients who developed HIV-associated non-Hodgkin lymphoma (NHL) in the era of combination antiretroviral therapy (cART). Design and setting: Multicohort collaboration of 33 European cohorts. Methods: We included all cART-naive patients enrolled in cohorts participating in the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) who were aged 16 years or older, started cART at some point after 1 January 1998 and developed NHL after 1 January 1998. Patients had to have a CD4 cell count after 1 January 1998 and one at diagnosis of the NHL. Survival and prognostic factors were estimated using Weibull models, with random effects accounting for heterogeneity between cohorts. Results: Of 67 659 patients who were followed up during 304 940 person-years, 1176 patients were diagnosed with NHL. Eight hundred and forty-seven patients (72%) from 22 cohorts met inclusion criteria. Survival at 1 year was 66% [95% confidence interval (CI) 63-70%] for systemic NHL (n = 763) and 54% (95% CI: 43-65%) for primary brain lymphoma (n = 84). Risk factors for death included low nadir CD4 cell counts and a history of injection drug use. Patients developing NHL on cART had an increased risk of death compared with patients who were cART naive at diagnosis. Conclusion: In the era of cART two-thirds of patients diagnosed with HIV-related systemic NHL survive for longer than 1 year after diagnosis. Survival is poorer in patients diagnosed with primary brain lymphoma. More advanced immunodeficiency is the dominant prognostic factor for mortality in patients with HIV-related NHL.
Published: 2009
Full Text: View/download PDF

14. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.

Author: null, null, Judd, Ali, Chappell, Elizabeth, Turkova, Anna, Le Coeur, Sophie, Noguera-Julian, Antoni, Goetghebuer, Tessa, Doerholt, Katja, Galli, Luisa, Pajkrt, Dasja, Marques, Laura, Collins, Intira J., Gibb, Diana M., González Tome, Maria Isabel, Navarro, Marisa, Warszawski, Josiane, Königs, Christoph, Spoulou, Vana, Prata, Filipa, and Chiappini, Elena
Subjects: *MORTALITY, *HIGHLY active antiretroviral therapy, *AIDS, *HIV infections
Abstract: Background: Published estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries, including some in Western and Central Europe (W&CE), Eastern Europe (Russia and Ukraine), and Thailand.Methods and Findings: Children with perinatal HIV aged <18 years initiating cART were followed until their 21st birthday, transfer to adult care, death, loss to follow-up, or last visit up until 31 December 2013. Rates of death and first AIDS-defining events were calculated. Baseline and time-updated risk factors for early/late (≤/>6 months of cART) death and progression to AIDS were assessed. Of 3,526 children included, 32% were from the United Kingdom or Ireland, 30% from elsewhere in W&CE, 18% from Russia or Ukraine, and 20% from Thailand. At cART initiation, median age was 5.2 (IQR 1.4-9.3) years; 35% of children aged <5 years had a CD4 lymphocyte percentage <15% in 1997-2003, which fell to 15% of children in 2011 onwards (p < 0.001). Similarly, 53% and 18% of children ≥5 years had a CD4 count <200 cells/mm3 in 1997-2003 and in 2011 onwards, respectively (p < 0.001). Median follow-up was 5.6 (2.9-8.7) years. Of 94 deaths and 237 first AIDS-defining events, 43 (46%) and 100 (42%) were within 6 months of initiating cART, respectively. Multivariable predictors of early death were: being in the first year of life; residence in Russia, Ukraine, or Thailand; AIDS at cART start; initiating cART on a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen; severe immune suppression; and low BMI-for-age z-score. Current severe immune suppression, low current BMI-for-age z-score, and current viral load >400 c/mL predicted late death. Predictors of early and late progression to AIDS were similar. Study limitations include incomplete recording of US Centers for Disease Control (CDC) disease stage B events and serious adverse events in some countries; events that were distributed over a long time period, and that we lacked power to analyse trends in patterns and causes of death over time.Conclusions: In our study, 3,526 children and adolescents with perinatal HIV infection initiated antiretroviral therapy (ART) in countries in Europe and Thailand. We observed that over 40% of deaths occurred ≤6 months after cART initiation. Greater early mortality risk in infants, as compared to older children, and in Russia, Ukraine, or Thailand as compared to W&CE, raises concern. Current severe immune suppression, being underweight, and unsuppressed viral load were associated with a higher risk of death at >6 months after initiation of cART. [ABSTRACT FROM AUTHOR]
Published: 2018
Full Text: View/download PDF

15. Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK.

Author: Judd, Ali, Collins, Intira Jeannie, Parrott, Francesca, Hill, Teresa, Jose, Sophie, Ford, Deborah, Asad, Hibo, Gibb, Diana M., and Sabin, Caroline
Subjects: *PERINATALLY-acquired HIV infections, *MATERNAL health services, *IMMUNOLOGY, *PEDIATRICS, *ADULT care facilities, *HEALTH outcome assessment
Abstract: Introduction: With improved survival, adolescents with perinatal HIV (PHIV) are transitioning from paediatric to adult care, but there are few published data on clinical outcomes post-transfer. Using linked data from patients in the national UK/ Ireland paediatric cohort (CHIPS) and an adult UK cohort of outpatient clinics (UK CHIC), we describe mortality and changes in immunological status post-transfer. Methods: Participants in CHIPS aged ≥13 years by the end of 2013 were linked to the UK CHIC database. Mixed effects models explored changes in CD4 count before and after transfer, including interactions between time and variables where interaction p < 0.05. Results: Of 1,215 paediatric participants aged ≥13 years, 271 (22%) had linked data in UK CHIC. One hundred and forty-six (53%) were female, median age at last visit in paediatric care was 17 [interquartile range, IQR 16,18] years, median duration in paediatric care was 11.8 [6.6,15.5] years, and in adult care was 2.9 [1.5,5.9] years. At last visit in paediatric care, 74% (n = 200) were on ART, increasing to 84% (n = 228, p = 0.001) at last visit in adult care. In the 12 months before leaving paediatric care, 92 (47%) had two consecutive viral loads >400 copies/mL or one viral load >10,000 copies/mL, and likewise 102 (52%) in the 12 months post-transfer (p = 0.79). Seven (3%) people died in adult care. In multivariable analysis, CD4 declined as patients approached transition with a greater decline in those with higher nadir CD4 count (mean rates of decline of 3, 13, 15, 30 cells/mm3 per year for those with nadir CD4 < 100, 100–199, 200–299 and ≥300 cells/mm3, respectively). Post-transition, CD4 continued to decline in some groups (e.g. black males, -20 (-34, -5) cells/mm3 per year post transition, p = 0.007)) while it improved in others. Overall CD4 was higher with later year of birth (14 (7, 21) cells/mm3 per later year). There was no effect of age at transfer or changing hospital at transfer on CD4. Conclusions: Our findings suggest that CD4 in adolescents with perinatal HIV in the UK was declining in the period before transition to adult care, and there was some reversal in this trend post-transfer in some groups. Across the transition period, CD4 was higher in those with later birth years, suggesting improvements in clinical care and/or transition planning over time. [ABSTRACT FROM AUTHOR]
Published: 2017
Full Text: View/download PDF

16. Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation.

Author: Goetghebuer, Tessa, Chenadec, Jerome Le, Haelterman, Edwige, Galli, Luisa, Dollfus, Catherine, Thorne, Claire, Judd, Ali, Keiser, Olivia, Ramos, Jose Tomas, Levy, Jack, and Warszawski, Josiane
Subjects: HIV infections, THERAPEUTICS, ANTIRETROVIRAL agents, IMMUNOLOGY, COHORT analysis, INFANT diseases, HEALTH outcome assessment
Abstract: The clinical benefit of antiretroviral therapy in infants is established. In this cohort collaboration, we compare immunological and virological response to treatment started before or after 3 months of age. Early initiation provides a better short-termresponse, althoughevolutionafter 12months of age is similar in both groups. [ABSTRACT FROM AUTHOR]
Published: 2012
Full Text: View/download PDF

17. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens

Author: Rojo-conejo, Pablo, Tookey, Pat, Lyall, Hermione, Goetghebuer, Tessa, Judd, Ali, Gibb, Di M., Warszawski, Josiane, Townsend, Claire, Ene, Luminita, Koenigs, Christoph, Noguera Julian, Antoni, Martino, Maurizio, Penazzato, Martina, Duong, Trinh, Lechenadec, Jerome, Chiappini, Elena, Rudin, Christoph, Thorne, Claire, Giaquinto, Carlo, Galli, Luisa, Castro, Hannah, Tudor-williams, Gareth, and Ramos, Jose T.
Subjects: 0303 health sciences, medicine.medical_specialty, Reverse-transcriptase inhibitor, 030306 microbiology, business.industry, Immunology, Odds ratio, Confidence interval, 3. Good health, Surgery, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Interquartile range, Internal medicine, Cohort, medicine, Immunology and Allergy, Protease inhibitor (pharmacology), 030212 general & internal medicine, business, Viral load, medicine.drug, Cohort study
Abstract: Objective: To investigate virological and immunological response to antiretroviral therapy (ART), and predictors of switching and interrupting treatment among infants starting ART across Europe.Design: Cohort study.Methods: Nine cohorts from 13 European countries contributed data on HIV-infected infants born 1996-2008 and starting ART before age 12 months. Logistic and linear regression, and competing risks methods were used to assess predictors of virological (viral load < 400 copies/ml) and immunological (change in CD4 Z-score) response, switching to second-line ART and treatment interruptions with viral load less than 400 copies/ml.Results: A total of 437 infants were followed for median 5.9 (interquartile range 2.3-7.6) years after starting ART; 30% had an AIDS diagnosis prior to ART initiation. 53% had suppressed viral load < 400 copies/ml at 12 months in 1996-1999, increasing to 77% in 2004-2008. Virological and immunological responses at 12 months varied by initial ART type (P < 0.001 and P = 0.03, respectively), with four-drug nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens being superior [virological response < 400 copies/ml adjusted odds ratio 3.00, 95% confidence interval (CI) 1.24-7.23; mean increase in CD4 Z-score coefficient 0.64, 95% CI 0.10-1.17] to both three-drug NNRTI-based (reference) and boosted protease inhibitor regimens which were similar. Rates of switching to second-line ART were lower among children starting four-drug NNRTI-based and boosted protease inhibitor-based regimens compared with three-drug NNRTI regimens (P = 0.03). Sixty five percent of infants remained on first-line ART without treatment interruption after 5 years.Conclusion: Effective and prolonged responses to first-line ART can now be achieved in infants starting early ART outside trial settings. Superior responses to four-drug NNRTI compared with boosted protease inhibitor or three-drug NNRTI regimens need further evaluation, as does treatment interruption following early ART. (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins
Full Text: View/download PDF

18. Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years

Author: Daniel Podzamczer, Cristina Mussini, Huldrych F. Günthard, Jade Ghosn, Peter Reiss, Xavier Duval, Ali Judd, Bernard Masquelier, Joan Masip, Pursuing Later Treatment Options, Alessandro Cozzi-Lepri, Laurence Meyer, Santiago Pérez-Hoyos, Giota Touloumi, Niels Obel, Rebecca Lodwick, Geneviève Chêne, Bruno Ledergerber, Antonella Castagna, Céline Fabre-Colin, Andrea Antinori, Federico García, Deenan Pillay, Jesper Kjaer, Maria Dorrucci, Roger Paredes, Sergio Lo Caputo, Claire Thorne, Josiane Warsawski, José Ramos, Dimitrios Paraskevis, Amanda Mocroft, Schlomo Staszewski, Stéphane De Wit, Ard van Sighem, Jens D Lundgren, Andrea De Luca, Ramón Teira, Andrew N. Phillips, Dominique Costagliola, Carlo Torti, Lodwick, Rebecca, Costagliola, Dominique, Reiss, Peter, Torti, Carlo, Teira, Ramon, Dorrucci, Maria, Ledergerber, Bruno, Mocroft, Amanda, Podzamczer, Daniel, Cozzi Lepri, Alessandro, Obel, Niel, Masquelier, Bernard, Staszewski, Schlomo, Garcia, Federico, De Wit, Stephane, Castagna, Antonella, Antinori, Andrea, Judd, Ali, Ghosn, Jade, Touloumi, Giota, Mussini, Cristina, Duval, Xavier, Ramos, Jose, Meyer, Laurence, Warsawski, Josiane, Thorne, Claire, Masip, Joan, Perez Hoyos, Santiago, Pillay, Deenan, van Sighem, Ard, Lo Caputo, Sergio, Guenthard, Huldrych, Paredes, Roger, De Luca, Andrea, Paraskevis, Dimitrio, Fabre Colin, Celine, Kjaer, Jesper, Chene, Genevieve, Lundgren Jens, D., Phillips Andrew, N., University of Zurich, Lodwick, R, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Infectious diseases
Subjects: Male, HAART, HIV Infections, Kaplan-Meier Estimate, 10234 Clinic for Infectious Diseases, Interquartile range, virologic failure, Treatment Failure, HIV, education.field_of_study, Incidence (epidemiology), Middle Aged, Viral Load, Europe, AIDS, Reverse Transcriptase Inhibitors, Female, Viral load, ART, medicine.drug, Adult, medicine.medical_specialty, COHERE, Adolescent, Anti-HIV Agents, Population, 610 Medicine & health, Article, Young Adult, Pharmacotherapy, Life Expectancy, Acquired immunodeficiency syndrome (AIDS), Internal medicine, Internal Medicine, medicine, Humans, education, Proportional Hazards Models, Ritonavir, business.industry, HIV Protease Inhibitors, medicine.disease, Regimen, 2724 Internal Medicine, Immunology, business
Abstract: BACKGROUND: Life expectancy of people with human immunodeficiency virus (HIV) is now estimated to approach that of the general population in some successfully treated subgroups. However, to attain these life expectancies, viral suppression must be maintained for decades. METHODS: We studied the rate of triple-class virologic failure (TCVF) in patients within the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) who started antiretroviral therapy (ART) that included a nonnucleoside reverse-transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r) from 1998 onwards. We also focused on TCVF in patients who started a PI/r-containing regimen after a first-line NNRTI-containing regimen failed. RESULTS: Of 45 937 patients followed up for a median (interquartile range) of 3.0 (1.5-5.0) years, 980 developed TCVF (2.1%). By 5 and 9 years after starting ART, an estimated 3.4% (95% confidence interval [CI], 3.1%-3.6%) and 8.6% (95% CI, 7.5%-9.8%) of patients, respectively, had developed TCVF. The incidence of TCVF rose during the first 3 to 4 years on ART but plateaued thereafter. There was no significant difference in the risk of TCVF according to whether the initial regimen was NNRTI or PI/r based (P = .11). By 5 years after starting a PI/r regimen as second-line therapy, 46% of patients had developed TCVF. CONCLUSIONS: The rate of virologic failure of the 3 original drug classes is low, but not negligible, and does not appear to diminish over time from starting ART. If this trend continues, many patients are likely to need newer drugs to maintain viral suppression. The rate of TCVF from the start of a PI/r regimen after NNRTI failure provides a comparator for studies of response to second-line regimens in resource-limited settings
Published: 2010

19. Response to combination antiretroviral therapy: Variation by age

Author: Collaboration of Observational HIV Epidemiological Research Europe Study Group, Sabin, Ca, Smith, Cj, d'Arminio Monforte, A, Battegay, M, Gabiano, C, Galli, L, Geelen, S, Gibb, D, Guiguet, M, Judd, A, Leport, C, Dabis, F, Pantazis, N, Porter, K, Raffi, F, Thorne, C, Torti, C, Walker, S, Warszawski, J, Wintergerst, U, Chene, G, Lundgren, J., Collaborators: Weller, I, Costagliola, D, Ledergerber, B, Lundgren, J, Touloumi, G, Meyer, L, Krause, Mm, Goujard, C, de Wolf, F, Reiss, P, Dorrucci, M, Sabin, C, Del Amo, J, Obel, N, Mocroft, A, Kirk, O, Staszewski, S, Perez Hoyos, S, Almeda, J, Antinori, A, Monforte, Ad, Tovo, Pier Angelo, Salzberger, B, Fatkenheuer, G, Ramos, J, Mussini, C, Tookey, P, Casabona, J, Miro, Jm, Castagna, A, de Wit, S, Teira, R, Garrido, M, Dedes, N, Phillips, A, Furrer, H, Egger, M, Newell, Ml, Sterne, J, Telentie, A., Sabin Caroline, A., Smith Colette, J., Monforte A., D'Arminio, Battegay, Manuel, Gabiano, Clara, Galli, Luisa, Geelen, Sibyl, Gibb, Diana, Guiguet, Marguerite, Judd, Ali, Leport, Catherine, Dabis, Francoi, Pantazis, Niko, Porter, Kholoud, Raffi, Francoi, Thorne, Claire, Torti, Carlo, Walker, Sarah, Warszawski, Josiane, Wintergerst, Uwe, Chene, Genevieve, Lundgren, Jen, Weller, Ian, Costagliola, Dominique, Ledergerber, Bruno, Touloumi, Giota, Meyer, Laurence, Krause Murielle, Mary, Goujard, Cecile, de Wolf, Frank, Reiss, Peter, Dorrucci, Maria, Sabin, Caroline, Del Amo, Julia, Obel, Niel, Mocroft, Amanda, Kirk, Ole, Staszewski, Schlomo, Perez Hoyos, Santiago, Almeda, Jesu, Antinori, Andrea, Tovo Pier, Angelo, Salzberger, Bernd, Fatkenheuer, Gerd, Ramos, Jose, Mussini, Cristina, Tookey, Pat, Casabona, Jordi, Miro Jose, M., Castagna, Antonella, de Wit, Stephane, Teira, Ramon, Garrido, Myriam, Dedes, Niko, Phillips, Andrew, Furrer, Hansjakob, Egger, Matthia, Newell Marie, Louise, Sterne, Jonathan, Telenti, Amalio, Other departments, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Infectious diseases
Subjects: Pediatrics, clinical outcome, HIV Infections, Virological response, Cohort Studies, Antiretroviral Therapy, Highly Active, Immunology and Allergy, Immunological response, Age Factor, HIV Infection, Child, Aged, 80 and over, immunological response, Clinical outcome, Medicine (all), Hazard ratio, Age Factors, Middle Aged, Viral Load, Europe, Infectious Diseases, Treatment Outcome, Child, Preschool, combination antiretroviral therapy, RNA, Viral, Survival Analysi, Viral load, Cohort study, Human, Combination antiretroviral therapy, Adult, medicine.medical_specialty, Adolescent, Anti-HIV Agents, Immunology, virological response, Infectious Disease, Age, Age Distribution, Acquired immunodeficiency syndrome (AIDS), medicine, Humans, Survival analysis, Aged, business.industry, Infant, Newborn, Anti-HIV Agent, Infant, medicine.disease, HIV infection, Antiretroviral therapy, Survival Analysis, Confidence interval, CD4 Lymphocyte Count, age, Cohort Studie, business
Abstract: Objective: To provide information on responses to combination antiretroviral therapy in children, adolescents and older HIV-infected persons. Design and setting: Multicohort collaboration of 33 European cohorts. Subjects: Forty-nine thousand nine hundred and twenty-one anti retroviral-naive individuals starting combination antiretroviral therapy from 1998 to 2006. Outcome measures: Time from combination antiretroviral therapy initiation to HIV RNA less than 50copies/ml (virological response), CD4 increase of more than 100cells/mu l (immunological response) and new AIDS/death were analysed using survival methods. Ten age strata were chosen: less than 2, 2-5, 6-12, 13-17, 18-29, 30-39 (reference group), 40-49, 50-54, 55-59 and 60 years or older; those aged 6 years or more were included in multivariable analyses. Results: The four youngest age groups had 223, 184, 219 and 201 individuals and the three oldest age groups had 2693, 1656 and 1613 individuals. Precombination antiretroviral therapy CD4 cell counts were highest in young children and declined with age. By 12 months, 53.7% (95% confidence interval: 53.2-54.1%) and 59.2% (58.7-59.6%) had experienced a virological and immunological response. The probability of virological response was lower in those aged 6-12 (adjusted hazard ratio: 0.87) and 13-17 (0.78) years, but was higher in those aged 50-54 (1.24), 55-59 (1.24) and at least 60 (1.18) years. The probability of immunological response was higher in children and younger adults and reduced in those 60 years or older. Those aged 55-59 and 60 years or older had poorer clinical outcomes after adjusting for the latest CD4 cell count. Conclusion: Better virological responses but poorer immunological responses in older individuals, together with low precombination antiretroviral therapy CD4 cell counts, may place this group at increased clinical risk. The poorer virological responses in children may increase the likelihood of emergence of resistance. (C) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. Objective: To provide information on responses to combination antiretroviral therapy in children, adolescents and older HIV-infected persons. Design and Setting: Multicohort collaboration of 33 European cohorts. Subjects: Forty-nine thousand nine hundred and twenty-one antiretroviral-naive individuals starting combination antiretroviral therapy from 1998 to 2006. Outcome Measures: Time from combination antiretroviral therapy initiation to HIV RNA less than 50 copies/ml (virological response), CD4 increase of more than 100 cells/Î¼l (immunological response) and new AIDS/death were analysed using survival methods. Ten age strata were chosen: less than 2, 2-5, 6-12, 13-17, 18-29, 30-39 (reference group), 40-49, 50-54, 55-59 and 60 years or older; those aged 6 years or more were included in multivariable analyses. Results: The four youngest age groups had 223, 184, 219 and 201 individuals and the three oldest age groups had 2693, 1656 and 1613 individuals. Precombination antiretroviral therapy CD4 cell counts were highest in young children and declined with age. By 12 months, 53.7% (95% confidence interval: 53.2-54.1%) and 59.2% (58.7-59.6%) had experienced a virological and immunological response. The probability of virological response was lower in those aged 6-12 (adjusted hazard ratio: 0.87) and 13-17 (0.78) years, but was higher in those aged 50-54 (1.24), 55-59 (1.24) and at least 60 (1.18) years. The probability of immunological response was higher in children and younger adults and reduced in those 60 years or older. Those aged 55-59 and 60 years or older had poorer clinical outcomes after adjusting for the latest CD4 cell count. Conclusion: Better virological responses but poorer immunological responses in older individuals, together with low precombination antiretroviral therapy CD4 cell counts, may place this group at increased clinical risk. The poorer virological responses in children may increase the likelihood of emergence of resistance. Â© 2008 Wolters Kluwer Health / Lippincott Williams & Wilkins.
Published: 2008

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

19 results on '"Judd, Ali"'

1. Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation

2. Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand

3. Predictors of faster virological suppression in early treated infants with perinatal HIV from Europe and Thailand

4. Sexual health of young people with perinatal HIV and HIV negative young people in England

5. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand : a cohort study

6. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

7. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study

8. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers

9. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord

10. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children. A EuroCoord-CHAIN-EPPICC Joint project

11. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

12. Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.

13. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

14. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.

15. Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK.

16. Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation.

17. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens

18. Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years

19. Response to combination antiretroviral therapy: Variation by age

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

19 results on '"Judd, Ali"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources